IP Library Granted Patent US 7,473,435
Granted Patent B2
US 7,473,435 · App. 11/033,925 · Granted Jan 6, 2009

Bioactive compositions form

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,473,435
App. No.
11/033,925
Granted
Jan 6, 2009
Kind
B2
Abstract

The present invention relates to isolated bioactive compositions containing bioactive fractions derived from Theacea plants. The present invention also relates to bioactive topical formulations containing the bioactive compositions. The present invention further relates to methods of using the bioactive compositions of the present invention, including, for example, methods for inhibiting inflammatory activity in skin tissue of a mammal, for protecting skin tissue of a mammal from ultraviolet light-induced damage, and for normalizing skin disorders in skin tissue of a mammal. The present invention also relates to methods for isolating bioactive fractions derived from cell juice or a cell walls component a Theacea plant.

Claims (42)

1. A method for isolating a bioactive fraction derived from cell juice of a Camellia plant, said method comprising:

providing fresh biomass of Camellia plant, wherein said fresh biomass comprises fresh Camellia plant biomass that has not undergone conventional tea processing;

separating the fresh biomass of the Camellia plant into cell juice and a cell walls component, wherein said separating comprises grinding, macerating, and pressing the fresh biomass to separate the fresh biomass into the cell juice and the cell walls component;

treating the cell juice under conditions effective to yield a bioactive fraction, said conditions comprising subjecting the cell juice to microwave treatment to induce coagulation, thereby yielding a coagulated membrane fraction and a non-coagulated portion of the cell juice, wherein said bioactive fraction is selected from the group consisting of a membrane fraction, a membrane fraction extract, a cytoplasm fraction extract, and a cell juice serum; and

isolating said bioactive fraction from the treated cell juice.

2. The method according to claim 1 , wherein said bioactive fraction is a membrane fraction.

3. The method according to claim 1 , wherein said bioactive fraction is a membrane fraction extract.

4. The method according to claim 1 , wherein said bioactive fraction is a cytoplasm fraction.

5. The method according to claim 1 , wherein said bioactive fraction is a cytoplasm fraction extract.

6. The method according to claim 1 , wherein said bioactive fraction is a cell juice serum.

7. The method according to claim 1 , wherein said Camellia plant is selected from the group consisting of Camellia sinensis, Camellia japonica, Camellia reticulate , and Camellia sasanqua.

8. The method according to claim 1 , wherein said isolating comprises

separating the coagulated membrane fraction from the non-coagulated portion, thereby yielding the membrane fraction.

9. The method according to claim 1 , wherein said isolating comprises

separating the coagulated membrane fraction from the non-coagulated portion, thereby yielding the membrane fraction; and

subjecting the membrane fraction to solvent extraction conditions with dimethyl sulfoxide, thereby yielding the membrane fraction extract.

10. The method according to claim 1 , wherein said isolating comprises

separating the coagulated membrane fraction from the non-coagulated portion, thereby yielding the non-coagulated portion; and

subjecting the non-coagulated portion to coagulation by isoelectric precipitation and centrifugation conditions, thereby yielding the precipitate comprising the cytoplasm fraction.

11. The method according to claim 1 , wherein said isolating comprises

separating the coagulated membrane fraction from the non-coagulated portion, thereby yielding the non-coagulated portion; and

subjecting the non-coagulated portion to coagulation by isoelectric precipitation and centrifugation conditions, thereby yielding the precipitate comprising the cytoplasm fraction; and

subjecting the cytoplasm fraction to solvent extraction conditions with dimethyl sulfoxide, thereby yielding the cytoplasm fraction extract.

12. The method according to claim 1 , wherein said isolating comprises

separating the coagulated membrane fraction from the non-coagulated portion, thereby yielding the non-coagulated portion; and

subjecting the non-coagulated portion to coagulation by isoelectric precipitation and centrifugation conditions, thereby yielding a supernatant liquid comprising the cell juice serum.

13. The method according to claim 1 , wherein said membrane fraction extract has a total catechin content of between about 15.0 and about 30.5 milligrams per gram of dry matter.

14. The method according to claim 1 , wherein said membrane fraction extract has a catechin content profile comprising:

between about 1.7 and about 3.3 milligrams of (−)-epigallocatechin per gram of dry matter of the membrane fraction extract,

between about 6.1 and about 10.2 milligrams of (+)-catechin per gram of dry matter of the membrane fraction extract,

between about 0.3 and about 1.1 milligrams of (−)-epicatechin per gram of dry matter of the membrane fraction extract,

between about 6.2 and about 12.5 milligrams of (−)-epigallocatechin gallate per gram of dry matter of the membrane fraction extract,

between about 0.007 and about 0.03 milligrams of (−)-gallocatechin gallate per gram of dry matter of the membrane fraction extract, and

between about 1.3 and about 3.3 milligrams of (−)-epicatechin gallate per gram of dry matter of the membrane fraction extract.

15. The method according to claim 1 , wherein said cell juice serum has a total catechin content of between about 8.0 and about 20.0 milligrams per gram of dry matter.

16. The method according to claim 1 , wherein said cell juice serum has a catechin content profile comprising:

between about 2.1 and about 4.4 milligrams of (−)-epigallocatechin per gram of dry matter of the cell juice serum,

between about 4.2 and about 8.6 milligrams of (+)-catechin per gram of dry matter of the cell juice serum,

between about 0.2 and about 2.0 milligrams of (−)-epicatechin per gram of dry matter of the cell juice serum,

between about 1.2 and about 3.2 milligrams of (−)-epigallocatechin gallate per gram of dry matter of the cell juice serum,

between about 0.01 and about 0.1 milligrams of (−)-gallocatechin gallate per gram of dry matter of the cell juice serum, and

between about 0.2 and about 1.3 milligrams of (−)-epicatechin gallate per gram of dry matter of the cell juice serum.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 10, 2020
From: THE BANK OF NOVA SCOTIA
To: AVOCA LLC; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES LLC
Reel/Frame 051557/0504 →
SECURITY AGREEMENT Recorded Jul 3, 2017
From: AVOCA, INC.; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES, INC.
To: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT
Reel/Frame 043084/0753 →
CHANGE OF NAME Recorded May 22, 2017
From: ISP INVESTMENTS INC.
To: ISP INVESTMENTS LLC
Reel/Frame 042521/0083 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2015
From: AKZO NOBEL SURFACE CHEMISTRY LLC; AKZO NOBEL CHEMICALS INTERNATIONA B.V.
To: ISP INVESTMENTS INC.
Reel/Frame 036583/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2011
From: INTEGRATED BOTANICAL TECHNOLOGIES, LLC
To: AKZO NOBEL SURFACE CHEMISTRY LLC
Reel/Frame 027406/0905 →